Enriched entity name Hit type Subjects with allergy (p-value) Subjects with allergy without asthma and AD (p-value) Subjects with allergic asthma and AD (p-value)
Immunoglobulins IgE Induces Airway Smooth Muscle Cell Proliferation Disease 0.05 0.02 >0.05
V(D)J Recombination Activation Biological process >0.05 0.01 0.01
IgE Receptors -> Targets in Lymphoid System and Blood Biomarkers >0.05 >0.05 0.01
Interleukins IL3 Expression Targets Biomarkers 0.04 0.02 0.03
IL17F Signaling in Bronchial Epithelial Cell in Asthma Disease 0.02 >0.05 >0.05
IL4 Expression Targets Biomarkers >0.05 >0.05 <0.01
IL10/STAT3 Signaling in M2 Macrophage and Retinal Angiogenesis Disease >0.05 >0.05 0.04
IL17 Signaling in Psoriasis Disease >0.05 >0.05 0.02
CD molecules CD80 -> STAT Expression Targets Biomarkers >0.05 0.02 >0.05
CD86 -> STAT Expression Targets Biomarkers >0.05 0.03 >0.05
CD80 -> NF-kB Expression Targets Biomarkers >0.05 0.04 >0.05
CD38/CD19 -> JUN/FOS/NF-kB Signaling in B-cell Proliferation Signal processing >0.05 0.03 >0.05
CD38 -> cADPR/Calcium Signaling Signal processing 0.04 >0.05 >0.05
CD157 -> cADPR/Calcium Signaling Signal processing 0.01 <0.01 >0.05
Mast cells Mast-Cells Activation in Atopic Dermatitis Disease 0.02 0.01 >0.05
Mast-Cell Activation without Degranulation through CRHR1 Signaling Biological processes 0.01 >0.05 >0.05
Receptor tyrosine kinases VEGFA -> FOXO3A Expression Targets Biomarkers >0.05 0.01 >0.05
VEGFR -> FOXO3A Signaling Signalling processes 0.04 0.01 >0.05
TGFA -> FOXO3A Expression Targets Biomarkers >0.05 >0.05 0.01
HBEGF -> FOXO3A Expression Target Biomarkers >0.05 >0.05 0.01
EREG -> FOXO3A Expression Target Biomarkers >0.05 >0.05 0.02